Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/html-api/html5-named-character-references.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/html-api/html5-named-character-references.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/rest-api/endpoints/class-wp-rest-autosaves-controller.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/rest-api/endpoints/class-wp-rest-autosaves-controller.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/class-wp-block-parser.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/class-wp-block-parser.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/fonts/class-wp-font-face.php on line 1

Warning: Uninitialized string offset 0 in /home/clients/bc5597821b53ab89da1ae64a09b52c9f/combioxinworldpress/wp-includes/fonts/class-wp-font-face.php on line 1
Combioxin | Restoring health in critically ill patients
Select Page

REVOLUTION IN THE TREATMENT OF SEVERE INFECTIONS

CAL02

Combioxin is a clinical-stage biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections.

The company entered into worldwide licensing agreement with Eagle Pharmaceuticals for the commercial rights to its pipeline.

CAL02

Novel first-in-class anti-toxin agent being developed for the treatment of severe community-acquired bacterial pneumonia.

The unique therapeutic approach of CAL02 consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections.

Received FDA Fast-Track and Qualified Infectious Disease Product (QIDP) designations.

Global Phase 2 clinical study underway.

LATEST NEWS

FDA grants Qualified Infectious Disease Product (QIDP) and Fast-Track Designations for CAL02 

June 13, 2023

Combioxin‘s licensee, Eagle Pharmaceuticals, announces acceptance of Investigational New Drug application to FDA for CAL02 for the treatment of severe community-acquired bacterial pneumonia

November 11, 2022

Pneumonia is the most common infection requiring hospitalization and admission to the intensive care unit (ICU), and is the third most common cause of death globally with 2.4 million deaths per year

There are >300 million cases per year

2’400 / day

CHILDREN < 5 YEARS DYING
OF PNEUMONIA

2.4 million

DEATHS CAUSED ANNUALLY
BY PNEUMONIA

Up to 50%

MORTALITY RATES OF
SEVERE PNEUMONIA

FOUNDING MEMBERS

Samareh Azeredo da Silveira

Managing Director

Frédéric Lajaunias

Managing Director